At a glance
ClinicalIndex Comparison RecordN/ACompleted· 252 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center Post Marketing Observational Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed HUMIRA® (Adalimumab) as Part of Routine Clinical Care in Russia
In Brief
An observational study for Rheumatoid Arthritis and 2 related conditions. Completed, enrolled 252 participants across 43 sites.
Detailed Summary
The primary objective of this post-marketing observational study was to obtain data on the characteristics (patient age/gender; disease type, severity and duration; disease specific treatment history; current concomitant medications; other relevant medical history) of patients prescribed adalimumab (Humira®) for rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) as part of routine clinical care in Russia.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesRussia
CollaboratorsScientific Research Institute of Rheumatology, Moscow, Almedis
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedJul 2010
Primary CompletionNov 2011
TodayJul 2026
First PostedJul 16, 2010
Enrollment StartJan 1, 2008
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 16.0 years ago